Author

Charlotte Quentin-Froignant

ORCID 0000-0003-2393-8408Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Franck GallardoiD· 3 shared Elie MarcheteauiD· 2 shared Luigi André AgrofoglioiD· 2 shared Sandrine Kappler‐Gratias· 2 shared Vincent RoyiD· 2 shared A. Proust· 1 shared Ann E. TollefsoniD· 1 shared Anna Cline-SmithiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

Franck GallardoORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MicrobiologyJournal of Hospital InfectionPeer-reviewedMay 4, 2026

Use of ANCHOR viruses to validate radiative, physical and chemical decontamination systems in operational conditions.

Franck Gallardo, V. Poirier, Charlotte Quentin-Froignant…·Elie Marcheteau

This paper validates ANCHOR viruses as a platform for evaluating disinfection methods across chemical, physical, and radiative modalities in operational conditions.

DOI 10.1016/j.jhin.2026.01.031

experimental assay

𝕏 PostBluesky

MicrobiologybioRxivPreprintFeb 20, 2025

LAVR-289, a new acyclo-nucleoside phosphonate having broad-spectrum activity against herpesviruses.

Sandrine Kappler‐Gratias, Charlotte Quentin-Froignant, Elie Marcheteau…·Franck Gallardo

This study evaluates LAVR-289, a new antiviral compound, showing broad-spectrum activity against herpesviruses and resistance to existing treatments.

DOI 10.1101/2025.02.20.639249

humanexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivPreprintFeb 20, 2025

LAVR-289, a New Orally Bioavailable Inhibitor of Adenovirus Replication in vitro and in vivo.

Charlotte Quentin-Froignant, Ann E. Tollefson, Anna Cline-Smith…·Franck Gallardo

This study evaluates LAVR-289, an acyclonucleoside phosphonate, showing potent antiviral activity against adenovirus in vitro and in vivo, with 100% survival in immunocompromised hamsters.

DOI 10.1101/2025.02.20.639236

mouseexperimental assay

𝕏 PostBluesky